Uniting Hearts and Pooling Strength, Galloping into a New Journey | The 2026 Annual Celebration of Hycells Concludes Successfully
Release Date:
2026-02-05 16:52
Unite as one and stride forward into a new journey.
Recently, the 2026 Hycells Annual Gala, themed “Uniting Hearts and Pooling Strengths for a New Leap Forward,” was grandly held at Club Med Joyview Anji Resort.
At the outset of the event, the Clinical, Marketing, Technical, and Operations departments each delivered their annual summary reports, systematically reviewing the achievements within their respective areas of responsibility, highlighting the accomplishments and lessons learned in 2025, and candidly analyzing the challenges and shortcomings currently being faced.
The photo shows work reports by Chen Peihua from the Operations Department and Zhang Jingjing from the Clinical Department.
Mr. Zhou Bin, General Manager of Hycells, delivered the final report, beginning by extending his sincerest gratitude to all colleagues. The year 2025 marks a milestone for Hycells: through the concerted efforts of the entire team, the company has successfully completed its strategic transformation and achieved a series of key milestones. The 2,000-square-meter GMP production facility of Wuxi Hycells Biotechnology is now essentially complete; the company has smoothly closed a Pre-A round of financing totaling tens of millions of yuan, thereby gaining recognition from the capital markets; and, leveraging its independently developed R&D platform, it has established an integrated service system encompassing “sample services—specialized products—technical service platform.” Hycells has thus established a core portfolio centered on primary immune cells, stem cells, and hepatocytes, covering HiXpan Registered trademark A distinctive product portfolio encompassing cell culture series, HiMag sorting kits, cell cryopreservation solutions, CAR-positive rate detection reagents, and more; furthermore, we have expanded our service offerings to include specialized technical services such as in vitro drug efficacy evaluation, drug immunogenicity assessment, and drug-induced hematotoxicity testing, providing customers with end-to-end, one-stop comprehensive solutions.
The photo shows General Manager Zhou Bin of Hycells delivering a work report.
Looking ahead, Hycells will continue to optimize its product portfolio, enhance the quality and production capacity of GMP-grade products, and consolidate its competitive edge in the domestic substitution segment. At the same time, the company will accelerate the global commercialization of primary cells and related reagents, consumables, and technical services, further strengthening its international market presence.
At the annual meeting, the company recognized and awarded bonuses to individuals and teams who demonstrated outstanding performance throughout the year, in order to motivate all employees to work diligently and grow together.
The photo shows the ceremony for individual and team awards.
Annual Meeting Performance
The cultural performance segment brought the atmosphere to a fever pitch, as thoughtfully choreographed acts from each department took the stage one after another: the Clinical Department delivered a creative rendition of “The Alliance of Dedication,” the Marketing Department treated the audience to a heartfelt duet by their “Prince of Love Songs,” the Operations Department energized the crowd with a lively medley of popular songs, and the Technology R&D Department wowed the audience with the hilariously entertaining “Congratulations on Your Fortune—The God of Wealth and His Chaotic Army.” Laughter and applause erupted again and again, blending together to create a sea of joy.
The photo shows the annual gala performance.
Between performances, several rounds of interactive games and prize draws were held, with generous gifts conveying the company’s sincere appreciation and best wishes to every team member. “Uniting Hearts and Pooling Strength, Galloping into a New Journey” is not only the theme of this year-end gala but also the shared conviction and guiding principle for all members of Heyou. Looking ahead, we will carry forward the achievements of the past and our unwavering confidence, working hand in hand to forge ahead, innovate, and embark together on a brand-new journey!
The photo shows the award-winning friends.
The photo shows a group shot of some of Hycells’s friends.
On the occasion of the Spring Festival, Hycells, together with all our colleagues, warmly wishes you a prosperous Year of the Horse and success at every turn. May we gallop forward in the new year like spirited steeds, embarking on a brand-new journey together!
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board